CMPS

Compass is a pre-revenue clinical biotech whose entire value rests on COMP360 psilocybin for treatment-resistant depression, and on the science the story just got dramatically better. Per the 10-K, BOTH pivotal Phase 3 trials hit their primary endpoint: COMP005 (single 25mg vs placebo, n=258) showed a 'highly statistically significant' -3.6 MADRS difference at six weeks (p<0.001), and COMP006 (n=581) hit with a -3.8-point difference (p<0.001) in February 2026. The FDA has accepted the company's meeting request to discuss a rolling submission. For a binary-outcome drug developer, this is the ballgame — the central efficacy risk has largely resolved in the bull's favor, with Breakthrough Therapy designation and a first-in-class TRD profile behind it.

The financials, however, are precarious and pull hard the other way. There is no revenue. The FY2025 net loss widened to -$288M (from -$155M), operating loss was -$179M, and the company burned -$157M of operating cash against just $150M of cash on hand — roughly one year of runway. Stockholders' equity is NEGATIVE at -$52.8M (liabilities/equity -4.98x), and current liabilities exploded +628% to $248M against $191M of current assets, leaving negative working capital. Shares already grew 39% YoY to 129M. The math is unavoidable: Compass must raise capital, and a positive-data biotech with a year of cash will dilute — the question is how much, not whether.